![Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/b383c608-ca13-4c76-9b23-d4f810ca8d9c/jah35265-fig-0001.png)
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association
![1610758-20-7 | O-(2-Ethylbutyl) Dabigatran Ethyl Ester | N-[[2-[[[4-[[[(2-Ethylbutoxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine Ethyl Ester; Dabigatran Impurity C | C₃₇H₃₈N₇O₅ | TRC 1610758-20-7 | O-(2-Ethylbutyl) Dabigatran Ethyl Ester | N-[[2-[[[4-[[[(2-Ethylbutoxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine Ethyl Ester; Dabigatran Impurity C | C₃₇H₃₈N₇O₅ | TRC](https://www.trc-canada.com/prod-img/E900655.png)
1610758-20-7 | O-(2-Ethylbutyl) Dabigatran Ethyl Ester | N-[[2-[[[4-[[[(2-Ethylbutoxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine Ethyl Ester; Dabigatran Impurity C | C₃₇H₃₈N₇O₅ | TRC
![Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation - Zachary Stacy, Sara Richter, 2017 Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation - Zachary Stacy, Sara Richter, 2017](https://journals.sagepub.com/cms/10.1177/1076029616634886/asset/images/large/10.1177_1076029616634886-fig1.jpeg)